Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluating clinical trial data: outcome measures.

R R Conley1

  • 1Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA.

The Journal of Clinical Psychiatry
|May 31, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of the special patient with schizophrenia.

Dialogues in clinical neuroscience·2011
Same author

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.

The pharmacogenomics journal·2009
Same author

ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf.

Molecular psychiatry·2005
Same author

Assessment of capacity to give consent to research participation: state-of-the-art and beyond.

Journal of health care law & policy·2004
Same author

Measurement of antipsychotic-induced side effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement.

Human psychopharmacology·2003
Same author

Management of treatment resistance in schizophrenia.

Biological psychiatry·2001
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Finding better ways to measure treatment success is crucial for schizophrenia research. This study reviews outcome measures in clinical trials for atypical antipsychotics to improve patient care.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Research

Background:

  • Schizophrenia is a disabling illness requiring effective treatments.
  • Atypical antipsychotics are common but costly treatments for schizophrenia.
  • Measuring treatment success (outcomes) is vital for research and patient care.

Purpose of the Study:

  • To evaluate outcome measures used in 5 clinical trials of atypical antipsychotics.
  • To assess the utility of current outcome measures in schizophrenia treatment.
  • To propose future directions for outcome measurement in schizophrenia.

Main Methods:

  • Review of outcome measures from 5 published clinical trials.
  • Analysis of the focus of outcome measures (e.g., symptom reduction, cost reduction, patient-oriented outcomes).

Related Experiment Videos

  • Discussion of the strengths and limitations of various outcome measures.

    • Main Results:

    • Clinical trials vary in their focus for outcome measurement.
    • Some trials prioritize cost-saving outcomes (e.g., rehospitalization) over patient-centered outcomes.
    • The usefulness of different outcome measures requires careful consideration.

    Conclusions:

    • Standardized and patient-centered outcome measures are needed for schizophrenia research.
    • Future research should focus on developing and validating comprehensive outcome measures.
    • Optimizing outcome measurement can lead to more effective schizophrenia interventions.